文章：

急性髓系白血病对小分子药物的耐药机制

Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia

原文发布日期：15 September 2023

DOI: 10.3390/cancers15184573

类型: Article

开放获取: 是

英文摘要：

In recent years, great progress has been made in the therapy of AML by targeting cellular processes associated with specific molecular features of the disease. Various small molecules inhibiting FLT3, IDH1/IDH2, and BCL2 have already gained approval from the respective authorities and are essential parts of personalized therapeutic regimens in modern therapy of AML. Unfortunately, primary and secondary resistance to these inhibitors is a frequent problem. Here, we comprehensively review the current state of knowledge regarding molecular processes involved in primary and secondary resistance to these agents, covering both genetic and nongenetic mechanisms. In addition, we introduce concepts and strategies for how these resistance mechanisms might be overcome.

摘要翻译： 

近年来，通过靶向与特定分子特征相关的细胞过程，急性髓系白血病的治疗取得了重大进展。多种抑制FLT3、IDH1/IDH2和BCL2的小分子药物已获得相关监管机构批准，成为现代AML个体化治疗方案的重要组成部分。然而，对这些抑制剂的原发性和继发性耐药仍是常见难题。本文系统综述了当前关于这些药物原发及继发性耐药所涉及分子机制的研究进展，涵盖遗传与非遗传性耐药机制。此外，我们还探讨了可能克服这些耐药机制的策略与理念。

原文链接：

Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia